Gossamer Bio (NASDAQ:GOSS) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a report released on Thursday morning,Benzinga reports. The brokerage currently has a $10.00 price target on the stock. HC Wainwright also issued estimates for Gossamer Bio’s FY2029 earnings at $0.59 EPS.

Gossamer Bio Price Performance

GOSS stock opened at $0.96 on Thursday. The stock has a market capitalization of $218.37 million, a PE ratio of -3.01 and a beta of 1.81. The company’s 50-day moving average is $0.86 and its 200-day moving average is $0.90. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. Gossamer Bio has a 1 year low of $0.50 and a 1 year high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $9.48 million for the quarter, compared to the consensus estimate of $4.52 million. Equities research analysts expect that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Gossamer Bio

Large investors have recently added to or reduced their stakes in the business. US Bancorp DE bought a new position in Gossamer Bio in the 3rd quarter valued at about $39,000. GSA Capital Partners LLP purchased a new stake in Gossamer Bio in the 3rd quarter valued at about $67,000. Algert Global LLC purchased a new stake in Gossamer Bio in the 2nd quarter valued at about $75,000. Sequoia Financial Advisors LLC increased its stake in Gossamer Bio by 26.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock valued at $117,000 after buying an additional 25,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Gossamer Bio by 67.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company’s stock valued at $279,000 after buying an additional 124,913 shares during the last quarter. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.